Results 201 to 210 of about 199,032 (289)

A Catalytic Osmium Redox Couple Collapses Cancer Redox Balance

open access: yesAdvanced Science, EarlyView.
A stable Os(III)/Os(IV) redox couple is developed to disrupt the tumor cell redox balance by concurrently catalyzing ROS generation and GSH depletion. Osmium‐treated cells exhibit multiple cell death pathways, including apoptosis, ferroptosis, and immunogenic cell death.
Wan‐Qiong Huang   +9 more
wiley   +1 more source

Lighting up Macrophage Reprogramming Assists Immunosuppressive Niche Modulation in Primary Tumors and Tumor‐Draining Lymph Nodes of Breast Cancer

open access: yesAdvanced Science, EarlyView.
This study develops an intelligent NIR‐II‐responsive nanoplatform to combat immunosuppression in breast cancer. It enables real‐time visualization of macrophage activity via “off‐on” fluorescence while simultaneously reprogramming macrophages through the CSF‐1R and CD47‐SIRPα pathways.
Yingbo Li   +14 more
wiley   +1 more source

Efficacy of Immune Checkpoint Inhibitors and Oncoviruses in Solid Tumors. [PDF]

open access: yesClin Cancer Res
Mechahougui H   +9 more
europepmc   +1 more source

Master Regulator SMC1A, Stabilized by N6‐Methyladenosine Reader IGF2BP1, Promotes HCC Progression Through Facilitating Enhancer–Promoter Interaction of Nestin

open access: yesAdvanced Science, EarlyView.
IGF2BP1‐mediated m6A stabilization sustains SMC1A expression, enabling cohesin‐associated chromatin regulation of Nestin in hepatocellular carcinoma. This work reveals an epitranscriptomic‐chromatin‐cytoskeletal regulatory axis linked to malignant phenotypes and identifies SMC1A as a biologically relevant vulnerability in HCC.
Zhenxiang Peng   +7 more
wiley   +1 more source

Mechanism‐Informed Machine Learning Enables Discovery of Oncolytic Peptides for Cancer Immunotherapy

open access: yesAdvanced Science, EarlyView.
MISPOP integrates ensemble learning with membrane‐active physicochemical priors to identify Dermaseptin‐S9, a natural oncolytic peptide that disrupts tumor membranes, triggers immunogenic cell death, and shows strong antitumor activity. The study illustrates a mechanism‐informed route from peptide sequence data to cancer immunotherapy leads.
Wen Zhang   +11 more
wiley   +1 more source

BCMA‐Engineered Dendritic Cell‐Derived Exosomes as Bi‐Functional Therapeutics Orchestrating Cytokine Sequestration and Immune Activation for Multiple Myeloma

open access: yesAdvanced Science, EarlyView.
A dual‐function cell‐free therapeutic based on DC2.4 cell‐derived exosomes engineered to display BCMA. (Left) Soluble Ligand Sequestration (Decoy Function): DB Exo act as molecular decoys that predominantly sequester soluble APRIL with partial BAFF attenuation, effectively disrupting the NF‐κB survival signaling axis and suppressing myeloma cell ...
Yuqing Zeng   +5 more
wiley   +1 more source

ZDHHC17‐Mediated CDK4 Palmitoylation Drives Cell Cycle Progression and Orchestrates Cancer Immune Surveillance

open access: yesAdvanced Science, EarlyView.
ZDHHC17 palmitoylates CDK4, which together with TRAF6‐mediated ubiquitination, drives cell cycle progression and immune surveillance, revealing a rational combination of CDK4 inhibitors with immune checkpoint blockers for ZDHHC17‐driven cancers. ABSTRACT Uncontrolled cell cycle progression is a hallmark of cancer, tightly regulated by both intrinsic ...
Zekang Wang   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy